Molecular Surveillance of Malaria in Tanzania Phase 2 (MSMT2)

Objectives

The goal of the project is to conduct Malaria Molecular Surveillance (MMS) in Tanzania to inform the National Malaria Control Program (NMCP) through extensive national surveillance of antimalarial resistance and pfhrp2/3 gene deletions.

The specific objectives of the projects are:

• To conduct antimalarial resistance and histidine rich protein 2/3 (hrp2/3) gene  deletions surveillance on a national scale to inform NMCP decision making
• To build serological capacity for detection of antigens used in rapid diagnostic tests (RDTs) and vector genomic surveillance (secondary objectives)
• To conduct antimalarial resistance modelling in collaboration with colleagues at Ifakara Health Institute (IHI) and the Institute for Disease Modelling (IDM)
• To deliver training and capacity building to NPHL to ensure sustainability of MMS

This is the second phases of the project on Molecular Surveillance of Malaria in Tanzania (MSMT) which was initiated in Tanzania in May 2020. The first phase (MSMT1) was undertaken with funding from the Bill and Melinda Gates Foundation (from May 2020 to April 2024) to build the comprehensive capacity for malaria molecular surveillance (MMS) to support policy and decision making for malaria control/elimination. This second phase (MSMT2) is a continuation of MSMT1, funded by Bill and Melinda Gates Foundation to further scale-up, strengthen and sustain MMS in Tanzania.